- Home
- LFS vs PYPD Comparison
LFS vs PYPD Comparison
Compare LFS & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFS | PYPD |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | Japan | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.7M | 77.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | LFS | PYPD |
|---|---|---|
| Price | $2.27 | $4.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 372.0K | 47.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $2.30 |
| 52 Week High | $12.49 | $5.12 |
Technical Indicators
Market Signals| Indicator | LFS | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 46.60 |
| Support Level | $2.22 | $4.26 |
| Resistance Level | $3.89 | $5.05 |
| Average True Range (ATR) | 0.32 | 0.20 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 9.49 | 46.57 |
Price Performance
Historical ComparisonAbout LFS LEIFRAS Co. Ltd. American Depositary Shares
Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.